Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CRMD NASDAQ:HUMA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.86+2.3%$3.77$1.16▼$4.89$672.46M0.762.09 million shs108,708 shsCRMDCorMedix$8.03+3.9%$7.00$6.13▼$17.43$631.83M1.462.03 million shs302,693 shsHUMAHumacyte$0.92+1.8%$0.87$0.55▼$2.93$202.93M2.316.19 million shs816,320 shsZVRAZevra Therapeutics$10.84+2.2%$9.63$7.16▼$13.16$633.89M0.881.00 million shs330,157 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+7.71%+12.56%+13.10%+34.18%+271.09%CRMDCorMedix-0.77%+2.11%+9.65%-1.40%-14.40%HUMAHumacyte+5.45%+6.42%+40.40%-5.88%-28.42%ZVRAZevra Therapeutics+5.36%+7.17%+12.87%+18.68%+32.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.86+2.3%$3.77$1.16▼$4.89$672.46M0.762.09 million shs108,708 shsCRMDCorMedix$8.03+3.9%$7.00$6.13▼$17.43$631.83M1.462.03 million shs302,693 shsHUMAHumacyte$0.92+1.8%$0.87$0.55▼$2.93$202.93M2.316.19 million shs816,320 shsZVRAZevra Therapeutics$10.84+2.2%$9.63$7.16▼$13.16$633.89M0.881.00 million shs330,157 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+7.71%+12.56%+13.10%+34.18%+271.09%CRMDCorMedix-0.77%+2.11%+9.65%-1.40%-14.40%HUMAHumacyte+5.45%+6.42%+40.40%-5.88%-28.42%ZVRAZevra Therapeutics+5.36%+7.17%+12.87%+18.68%+32.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.00126.38% UpsideCRMDCorMedix 2.63Moderate Buy$15.0086.73% UpsideHUMAHumacyte 2.75Moderate Buy$7.71740.34% UpsideZVRAZevra Therapeutics 2.78Moderate Buy$23.00112.14% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, ACRS, ZVRA, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.004/28/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.004/28/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/28/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/27/2026CRMDCorMedix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.004/27/2026CRMDCorMedix D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M86.67N/AN/A$0.85 per share5.72CRMDCorMedix$311.71M2.02$2.08 per share3.86$5.14 per share1.56HUMAHumacyte$2.04M99.91N/AN/A$0.02 per share45.90ZVRAZevra Therapeutics$106.47M6.02$1.02 per share10.62$2.75 per share3.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.53N/AN/AN/A-829.58%-52.04%-35.91%5/6/2026 (Estimated)CRMDCorMedix$163.05M$2.004.0357.38N/A52.31%52.30%29.46%5/6/2026 (Estimated)HUMAHumacyte-$40.83M-$0.20N/AN/AN/A-1,998.87%-990.48%-74.79%5/12/2026 (Estimated)ZVRAZevra Therapeutics$83.23M$1.338.068.34N/A78.17%57.42%26.03%5/6/2026 (Estimated)Latest HUMA, ACRS, ZVRA, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ACRSAclaris Therapeutics-$0.16N/AN/AN/A$1.24 millionN/A5/12/2026Q1 2026HUMAHumacyte-$0.10N/AN/AN/A$1.46 millionN/A5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06N/AN/AN/A$31.96 millionN/A3/27/2026Q4 2025HUMAHumacyte-$0.13-$0.13N/A-$0.13$1.35 million$0.47 million3/5/2026Q4 2025CRMDCorMedix$0.86$0.16-$0.70$0.16$127.02 million$128.62 million2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.363.36CRMDCorMedix0.362.111.94HUMAHumacyte20.083.692.95ZVRAZevra Therapeutics0.405.685.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CRMDCorMedix34.18%HUMAHumacyte44.71%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%CRMDCorMedix3.10%HUMAHumacyte5.10%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableCRMDCorMedix3078.44 million76.01 millionOptionableHUMAHumacyte150222.02 million210.70 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableHUMA, ACRS, ZVRA, and CRMD HeadlinesRecent News About These CompaniesZevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comZevra Therapeutics Announces Details for Q1 2026 Financial Results CallApril 23, 2026 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 16, 2026 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street ZenApril 11, 2026 | marketbeat.comStratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRAApril 7, 2026 | marketbeat.comZevra Ties NPC Testing Push To Valuation Gap And New CFOMarch 22, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy†by AnalystsMarch 22, 2026 | defenseworld.netDZevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)March 20, 2026 | globenewswire.comBTIG initiates coverage of Zevra Therapeutics (ZVRA) with buy recommendationMarch 16, 2026 | msn.comZevra shares jump after selling SDX portfolio for $50MMarch 16, 2026 | msn.comZevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 MillionMarch 16, 2026 | globenewswire.comCan Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?March 13, 2026 | uk.finance.yahoo.comZevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by ...March 11, 2026 | finance.yahoo.comIs Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price PerformanceMarch 11, 2026 | finance.yahoo.comGeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type CMarch 10, 2026 | finance.yahoo.comZevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial ModelMarch 10, 2026 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Q4 FY2025 earnings call transcriptMarch 10, 2026 | finance.yahoo.comZevra Therapeutics: Zevra Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 10, 2026 | finanznachrichten.deZVRA stock soars on upbeat Q4 results, optimism for EMA approval of Niemann-Pick disease treatmentMarch 10, 2026 | msn.comZevra Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 9, 2026 | markets.businessinsider.comZevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call TranscriptMarch 9, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026OpenAI Shutters Sora: A Win for Meta Platforms Amid a Rocky StretchBy Leo Miller | April 8, 2026HUMA, ACRS, ZVRA, and CRMD Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.86 +0.11 (+2.29%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.CorMedix NASDAQ:CRMD$8.03 +0.30 (+3.92%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Humacyte NASDAQ:HUMA$0.92 +0.02 (+1.79%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Zevra Therapeutics NASDAQ:ZVRA$10.84 +0.23 (+2.19%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
